The Canadian Cardiovascular Society and Canadian Association of Interventional Cardiology issued updated guidelines for the use of antiplatelet therapy (APT) to prevent atherosclerotic cardiovascular disease. The guidelines provide recommendations for the use of acetylsalicylic acid in primary prevention, duration of dual APT (DAPT) after percutaneous coronary intervention, choice of potent DAPT for patients with acute coronary syndrome, and DAPT management for patients who need coronary artery bypass grafting surgery. The update also emphasizes shared decision-making between patients and their doctors to tailor antiplatelet therapy based on individual cardiovascular risk and risk of bleeding. The guidelines are published in the Canadian Journal of Cardiology.
Source link
Guidelines updated for use of antiplatelet therapy for atherosclerotic CVD
